The NIH (National Institute of Health) of the United States has started a clinical trial for the purpose of assessing the response of the antibody to the novel corona virus booster vaccine in the people that have autoimmune disease, who does not respond to the first dose of the novel corona virus vaccine.
The trial is also going to investigate whether halting the immunosuppressive therapy for the autoimmune disease, which will be improving the response of antibody for the additional dose of a novel corona virus vaccine in such type of the patients.
Anthony Fauci, director of the National Institute of Allery and Infectious Diseases (NIAID), said, most of the people, who are having an autoimmune disease, which will be requiring the immunosuppressive therapy, that mainly have poor immune system and all the approved and authorised novel corona virus vaccines, that is responsible for placing the individuals at the high risk for the disease.
Anthony Fauci also said, they are more determined for finding different ways for eliciting a protective immune response to the corona virus vaccines in this overall population, and this new clinical trial has been an important step in the process.
This new trial of NIAID, which is also called a corona virus booster vaccine in the autoimmune disease, that has initially been going to be including the people with one of the five autoimmune disease including pemphigus, systemic lupus or systemic sclerosis, rheumatoid arthritis and also multiple sclerosis.